Spain | Phase I/ Phase II | Oncology

[{"orgOrder":0,"company":"Laminar Pharma","sponsor":"Specialized Medical Services (SMS)-Oncology BV | Royal Marsden NHS Foundation Trust | Northern Institute for Cancer Research (Newcastle) | Vall d'Hebron Institute of Oncology | Instituto Oncol\u00f3gico IMQ | Onkologikoa, San Sebasti\u00e1n.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"LAM561","moa":"Cholesterol efflux","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Laminar Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laminar Pharma \/ Specialized Medical Services (SMS)-Oncology BV | Royal Marsden NHS Foundation Trust | Northern Institute for Cancer Research (Newcastle) | Vall d'Hebron Institute of Oncology | Instituto Oncol\u00f3gico IMQ | Onkologikoa, San Sebasti\u00e1n.","highestDevelopmentStatusID":"7","companyTruncated":"Laminar Pharma \/ Specialized Medical Services (SMS)-Oncology BV | Royal Marsden NHS Foundation Trust | Northern Institute for Cancer Research (Newcastle) | Vall d'Hebron Institute of Oncology | Instituto Oncol\u00f3gico IMQ | Onkologikoa, San Sebasti\u00e1n."},{"orgOrder":0,"company":"Laminar Pharma","sponsor":"Hackensack Meridian Health | Dana-Farber Cancer Institute | Laminar Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"LAM561","moa":"Cholesterol efflux","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Laminar Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laminar Pharma \/ Hackensack Meridian Health | Dana-Farber Cancer Institute | Laminar Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Laminar Pharma \/ Hackensack Meridian Health | Dana-Farber Cancer Institute | Laminar Pharma"},{"orgOrder":0,"company":"MEDSIR","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Balixafortide","moa":"C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MEDSIR","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MEDSIR \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MEDSIR \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Iadademstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Peptomyc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"OMO-103","moa":"Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Peptomyc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Peptomyc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Peptomyc \/ Undisclosed"},{"orgOrder":0,"company":"Peptomyc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Omomyc","moa":"Myc expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Peptomyc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Peptomyc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Peptomyc \/ Undisclosed"},{"orgOrder":0,"company":"Ability Pharma","sponsor":"Cleveland Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ibrilatazar","moa":"Peroxisome proliferator-activated receptor (PPAR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ability Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ability Pharma \/ Cleveland Clinic","highestDevelopmentStatusID":"7","companyTruncated":"Ability Pharma \/ Cleveland Clinic"},{"orgOrder":0,"company":"Ability Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibrilatazar","moa":"Peroxisome proliferator-activated receptor (PPAR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ability Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ability Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ability Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ability Pharma","sponsor":"CTI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"Ibrilatazar","moa":"||Peroxisome proliferator-activated receptor (PPAR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ability Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Ability Pharma \/ CTI Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Ability Pharma \/ CTI Life Sciences"},{"orgOrder":0,"company":"Ability Pharma","sponsor":"Hospital Vall d'Hebron | Institut Catal\u00e0 d'Oncologia | Hospital Cl\u00ednico Universitario de Valencia | Hospitales Universitarios Virgen del Roc\u00edo | Centre L\u00e9on B\u00e9rard | Institut Paoli-Calmettes | Gustave Roussy","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ibrilatazar","moa":"Peroxisome proliferator-activated receptor (PPAR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ability Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ability Pharma \/ Hospital Vall d'Hebron | Institut Catal\u00e0 d'Oncologia | Hospital Cl\u00ednico Universitario de Valencia | Hospitales Universitarios Virgen del Roc\u00edo | Centre L\u00e9on B\u00e9rard | Institut Paoli-Calmettes | Gustave Roussy","highestDevelopmentStatusID":"7","companyTruncated":"Ability Pharma \/ Hospital Vall d'Hebron | Institut Catal\u00e0 d'Oncologia | Hospital Cl\u00ednico Universitario de Valencia | Hospitales Universitarios Virgen del Roc\u00edo | Centre L\u00e9on B\u00e9rard | Institut Paoli-Calmettes | Gustave Roussy"},{"orgOrder":0,"company":"AGC Pharma Chemicals Europe","sponsor":"Ability Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Ibrilatazar","moa":"Peroxisome proliferator-activated receptor (PPAR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AGC Pharma Chemicals Europe","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AGC Pharma Chemicals Europe \/ Ability Pharma","highestDevelopmentStatusID":"7","companyTruncated":"AGC Pharma Chemicals Europe \/ Ability Pharma"},{"orgOrder":0,"company":"IDP Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"IDP-121","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IDP Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IDP Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"IDP Pharma \/ Undisclosed"},{"orgOrder":0,"company":"IDP Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"IDP-121","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IDP Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"IDP Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"IDP Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MEDSIR","sponsor":"Debiopharm | Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Debio 0123","moa":"WEE1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MEDSIR","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MEDSIR \/ Debiopharm | Gilead Sciences","highestDevelopmentStatusID":"7","companyTruncated":"MEDSIR \/ Debiopharm | Gilead Sciences"}]

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

Virtual Booth

Contact Supplier

Check COS database
Check USDMF database

Filters

Company Name

Year

DEALS // DEV.

Country

Sponsor

Therapeutic Area

Study Phase

Deal Type

Product Type

Dosage Form

Lead Product

Target

Filters

Reset Filter

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

AGC Pharma Chemicals Europe

Spain

CPhI India

Booth #RH.J01

Your reliable CDMO partner - agile, scalable, top-quality Small Molecule API & HPAPI solutions from concept to market

Lead Product(s) : Ibrilatazar

Therapeutic Area : Oncology

Study Phase : Phase I/ Phase II

Sponsor : Ability Pharma

Deal Size : Undisclosed

Deal Type : Collaboration

DEALS_DEV

AGC Pharma and AbilityPharma to Produce Innovative Treatment for Pancreatic Cancer

Details : The collaboration aims for the development of an API for the treatment of pancreatic cancer, ABTL0812 (ibrilatazar), currently in clinical trials.

Product Name : ABTL0812

Product Type : Miscellaneous

Upfront Cash : Undisclosed

July 16, 2024

Lead Product(s) : Ibrilatazar

Therapeutic Area : Oncology

Highest Development Status : Phase I/ Phase II

Sponsor : Ability Pharma

Deal Size : Undisclosed

Deal Type : Collaboration